TPLL-1 protocol of the German CLL study group (GCLLSG) - A prospective phase II trial of fludarabine phosphate, mitoxantrone and cyclophosphamide (FMC) followed by alemtuzumab consolidation in T-PLL

被引：0

作者：

Hopfinger, Georg ^{[1
]}

Busch, Raymond ^{[2
]}

Barbara, Eichhorst ^{[3
]}

Paula, Cramer ^{[3
]}

Gabriele, Kandler ^{[1
]}

Gunther, Fingerle-Rowson ^{[3
]}

Anna-Maria, Fink ^{[3
]}

Stephan, Stilgenbauer ^{[4
]}

Michael, Hallek ^{[3
]}

机构：

[1] Hanusch Hosp, Dept Med 3, Vienna, Austria

[2] Tech Univ Munich, Inst Med Stat, D-8000 Munich, Germany

[3] Klinik 1, Cologne, Germany

[4] Klinik 3, Ulm, Germany

来源：

BLOOD | 2007年 / 110卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2039

引用

页码：607A / 607A

页数：1

共 25 条

[1] T-PLL-1 protocol of the German CLL study group (GCLLSG) - A prospective phase II trial of fludarabine phosphate, mitoxantrone and cyclophosphamide (FMC) followed by alemtuzumab consolidation in T-PLL.
Hopfinger, G
Busch, R
Eichhorst, B
Kandler, G
Wendtner, C
Hallek, M
BLOOD, 2005, 106 (11) : 602A - 603A
[2] T-PLL-1 protocol of the German CLL study group (GCLLSG) - a prospective phase II trial of fludarabine phosphate, mitoxantrone and cyclophosphamide (FMC) followed by alemtuzumab consolidation as first-line treatment in T-PLL.
Hopfinger, G
Kandler, G
Koller, E
Schmitt, B
Aul, C
Frickhofen, N
Grabenhorst, U
Herold, M
Jaeger, U
Marquart, F
Busch, R
Hallek, M
BLOOD, 2003, 102 (11) : 674A - 674A
[3] SEQUENTIAL THERAPY OF FLUDARABINE, MITOXANTRONE AND CYCLOPHOSPHAMIDE (FMC) INDUCTION FOLLOWED BY ALEMTUZUMAB CONSOLIDATION IS EFFECTIVE AND SAFE IN PATIENTS WITH T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL) - RESULTS FROM A MULTICENTER PHASE II TRIAL OF THE GERMAN CLL STUDY GROUP
Hopfinger, G.
Busch, R.
Eichhorst, B.
Westermann, A.
Fink, A.
Cramer, P.
Weit, N.
Pflug, N.
Reinart, N.
Winkler, D.
Fingerle-Rowson, G.
Stilgenbauer, S.
Kandler, G.
Doehner, H.
Hallek, M.
Herling, M.
ANNALS OF ONCOLOGY, 2011, 22 : 124 - 124
[4] Induction Treatment with Alemtuzumab Combined with Polychemotherapy Containing Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) Followed By Alemtuzumab Maintenance in Patients with T-Cell Prolymphocytic Leukaemia (T-PLL): First Analysis of a Prospective Multicenter Phase-II-Trial (T-PLL2) Conducted By the German CLL Study Group (GCLLSG)
Pflug, Natali
Hopfinger, Georg
Cramer, Paula
Schrader, Alexandra
Weit, Nicole
Meister, Rita
Thiel, Miriam
Annolleck, Tanja
Westermann, Anne
Seiler, Till M.
Zenz, Thorsten
Duerig, Jan
Bahlo, Jasmin
Kreuzer, Karl-Anton
Stilgenbauer, Stephan
Fink, Anna-Maria
Eichhorst, Barbara
Hallek, Michael
Herling, Marco
BLOOD, 2014, 124 (21)
[5] New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance
Pflug, Natali
Cramer, Paula
Robrecht, Sandra
Bahlo, Jasmin
Westermann, Anne
Fink, Anna-Maria
Schrader, Alexandra
Mayer, Petra
Oberbeck, Sebastian
Seiler, Till
Zenz, Thorsten
Duerig, Jan
Kreuzer, Karl-Anton
Stilgenbauer, Stephan
Eichhorst, Barbara
Hallek, Michael
Herling, Marco
Hopfinger, Georg
LEUKEMIA & LYMPHOMA, 2019, 60 (03) : 649 - 657
[6] Fludarabine versus fludarabine plus cyclophosphamide as first line therapy of advanced chronic lymphocytic leukemia (CLL):: First interim analysis of a phase III study (CLL4 protocol) of the German CLL study group (GCLLSG).
Schmitt, BF
Bergmann, M
Busch, R
Wendtner, CM
Pasold, R
Anders, O
Sezer, O
Hurtz, HJ
Söling, U
Steinbrecher, C
Emmerich, B
Hallek, M
BLOOD, 2001, 98 (11) : 633A - 633A
[7] Fludarabine plus cyclophosphamide (FC) and dose intensified chlorambucil (DIC) for the treatment of chronic lymphocytic leukemia (CLL):: Results of two phase II studies (CLL2-protocol) of the german cll study group (GCLLSG).
Hallek, M
Wilhelm, M
Emmerich, B
Döhner, H
Fostitsch, HP
Sezer, O
Herold, M
Knauf, W
Busch, R
Schmitt, B
Wendtner, CM
Kuse, R
Freund, M
Franke, A
Schriever, F
Nerl, C
Thiel, E
Hiddemann, W
Brittinger, G
BLOOD, 1999, 94 (10) : 313A - 313A
[8] Fludarabine, mitoxantrone and cyclophosphamide combination therapy in relapsed chronic lymphocytic leukemia (CLL) with or without G-CSF: Results of the first interim ananlysis of a phase III study of the German CLL study group (GCLLSG).
Schmitt, BF
Franke, A
Burkhard, O
Schlag, R
Hopfinger, G
Stauch, M
Bergmann, M
Wendtner, CM
Busch, R
Emmerich, B
Hallek, N
BLOOD, 2002, 100 (11) : 364B - 364B
[9] Consolidation with alemtuzumab in first remission induces pronounced MRD reduction and clinical remissions -: Update on a randomized phase III trial of the German CLL study group (GCLLSG).
Ritgen, M
Schweighofer, C
Fingerle-Rowson, G
Eichhorst, B
Busch, R
Stilgenbauer, S
Döhner, H
Kneba, M
Hallek, M
Wendtner, CM
BLOOD, 2004, 104 (11) : 687A - 687A
[10] Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission - Experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL study group (GCLLSG).
Wendtner, CM
Ritgen, M
Schweighofer, CD
Fingerle-Rowson, G
Campe, H
Jaeger, G
Eichhorst, B
Busch, R
Diem, H
Engert, A
Stilgenbauer, S
Doehner, H
Kneba, M
Emmerich, B
Hallek, M
BLOOD, 2003, 102 (11) : 676A - 676A

← 1 2 3 →